Aptose Biosciences Reports 100% Response Rate in AML Trial With Tuspetinib Combination Therapy
I'm PortAI, I can summarize articles.
Aptose Biosciences reported a 100% response rate in AML patients using tuspetinib combination therapy in the TUSCANY trial. The regimen showed promising safety and antileukemic activity, achieving high remission rates across genetic subgroups. No dose-limiting toxicities were observed, and preliminary findings at the 160 mg dose level indicate early blast clearance and MRD-negativity. The data was presented at the ASH Annual Meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments